Drug Profile
Ubiquitin protein ligase inhibitor - Daiichi Sankyo/Rigel Pharmaceuticals
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Rigel Pharmaceuticals
- Developer Daiichi Sankyo Company
- Class Small molecules
- Mechanism of Action Ubiquitin-protein ligase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Cancer in Unknown (PO)
- 26 May 2016 This programme is still active
- 31 Dec 2013 Phase-I clinical trials in Cancer (PO)